Regional Covid-19 Resources and On Reserve Stats by Region Below:
Black = New Cases, Green = Recovered, Red = Deaths, Blue – Hospitalized, Purple – ISC reported total –  Updated Daily

BC
14 458 158 8,632 8,804
AB
9 1,046 185 20,082 20,311
SK
0 495 129 16,186 16,343
MB
4 901 155 25,118 25,283
ON
81 365 80 21,111 21,459
QC
86 115 26 13,653 13,793
Atlantic
0 14 9 4,614 4,658
North60
10 326 56 19,406 19,499
 

Experimental ALS drug OK’d by Health Canada – CBC

Approval fast-tracks access while waiting for more data and studies; U.S. still reviewing

Jun 13, 2022

Health Canada has approved an experimental drug for amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease, as uncertainty persists about the drug’s clinical benefit.

Amylyx Pharmaceuticals said in a press release Monday that Canada is the first country in the world to give the regulatory green light to Albrioza as a treatment for the devastating neurodegenerative disease.

Health Canada granted its approval under a policy that aims to accelerate market access to promising drugs for serious diseases, with conditions including that the Massachusetts-based manufacturer provide more data and studies.

The regulator’s U.S. counterpart, the Food and Drug Administration (FDA), has deemed it safe but continues to review Albrioza after an independent advisory committee narrowly voted earlier this year that the available evidence on the drug’s effectiveness didn’t meet the threshold for approval. The FDA is expected to make its decision on Sept. 29 after pushing the date by three months to allow for more time to review additional analyses from Amylyx’s clinical studies.

Read more: https://www.cbc.ca/news/health/health-canada-als-drug-albrioza-1.6487460

NationTalk Partners & Sponsors Learn More